Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 45

1.

Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis.

Reece DE, Hegenbart U, Sanchorawala V, Merlini G, Palladini G, Bladé J, Fermand JP, Hassoun H, Heffner L, Kukreti V, Vescio RA, Pei L, Enny C, Esseltine DL, van de Velde H, Cakana A, Comenzo RL.

Blood. 2014 Sep 8. pii: blood-2014-04-568329. [Epub ahead of print]

PMID:
25202139
[PubMed - as supplied by publisher]
2.

Phase I-II trial of oral cyclophosphamide, prednisone and lenalidomide for the treatment of patients with relapsed and refractory multiple myeloma.

Reece DE, Masih-Khan E, Atenafu EG, Jimenez-Zepeda VH, Anglin P, Chen C, Kukreti V, Mikhael JR, Trudel S.

Br J Haematol. 2014 Aug 22. doi: 10.1111/bjh.13100. [Epub ahead of print]

PMID:
25146584
[PubMed - as supplied by publisher]
3.

Computerized prescriber order entry in the outpatient oncology setting: from evidence to meaningful use.

Kukreti V, Cosby R, Cheung A, Lankshear S; ST Computerized Prescriber Order Entry Guideline Development Group.

Curr Oncol. 2014 Aug;21(4):e604-12. doi: 10.3747/co.21.1990. Review.

PMID:
25089110
[PubMed]
Free PMC Article
4.

Long-term survival with cyclophosphamide, bortezomib and dexamethasone induction therapy in patients with newly diagnosed multiple myeloma.

Reeder CB, Reece DE, Kukreti V, Mikhael JR, Chen C, Trudel S, Laumann K, Vohra H, Fonseca R, Bergsagel PL, Leis JF, Tiedemann R, Stewart AK.

Br J Haematol. 2014 Jun 30. doi: 10.1111/bjh.13004. [Epub ahead of print] No abstract available.

PMID:
24974945
[PubMed - as supplied by publisher]
5.

Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for the treatment of secondary plasma cell leukemia.

Jimenez-Zepeda VH, Reece DE, Trudel S, Chen C, Tiedemann R, Kukreti V.

Leuk Lymphoma. 2014 Jun 27:1-4. [Epub ahead of print] No abstract available.

PMID:
24884320
[PubMed - as supplied by publisher]
6.

Tolerability of Velcade (Bortezomib) subcutaneous administration using a maximum volume of 3 mL per injection site.

Ng P, Incekol D, Lee R, Paisley E, Dara C, Brandle I, Kaufman M, Chen C, Trudel S, Tiedemann R, Reece D, Kukreti V.

J Oncol Pharm Pract. 2014 Apr 29. [Epub ahead of print]

PMID:
24781451
[PubMed - as supplied by publisher]
7.

Toward successful migration to computerized physician order entry for chemotherapy.

Jeon J, Taneva S, Kukreti V, Trbovich P, Easty AC, Rossos PG, Cafazzo JA.

Curr Oncol. 2014 Apr;21(2):e221-8. doi: 10.3747/co.21.1759.

PMID:
24764707
[PubMed]
Free PMC Article
8.

Intermittent granulocyte colony-stimulating factor for neutropenia management in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone.

Sun HL, Atenafu EG, Yeboah E, Reece DE, Trudel S, Kukreti V, Masih-Khan E, Winter A, Chen C.

Leuk Lymphoma. 2014 Jul 7:1-8. [Epub ahead of print]

PMID:
24738975
[PubMed - as supplied by publisher]
9.

Intensive care unit acquired weakness in children: Critical illness polyneuropathy and myopathy.

Kukreti V, Shamim M, Khilnani P.

Indian J Crit Care Med. 2014 Feb;18(2):95-101. doi: 10.4103/0972-5229.126079.

PMID:
24678152
[PubMed]
Free PMC Article
10.

Long-term follow-up of a phase 2 trial of single agent lenalidomide in previously untreated patients with chronic lymphocytic leukaemia.

Chen CI, Paul H, Wang T, Le LW, Dave N, Kukreti V, Nong Wei E, Lau A, Bergsagel PL, Trudel S.

Br J Haematol. 2014 Jun;165(5):731-3. doi: 10.1111/bjh.12785. Epub 2014 Feb 24. No abstract available.

PMID:
24611934
[PubMed - indexed for MEDLINE]
11.

Implementation of a pediatric rapid response team: experience of the Hospital for Sick Children in Toronto.

Kukreti V, Gaiteiro R, Mohseni-Bod H.

Indian Pediatr. 2014 Jan;51(1):11-5.

PMID:
24561462
[PubMed - indexed for MEDLINE]
Free Article
12.

Chemoimmunotherapy resistant follicular lymphoma: predictors of resistance, association with transformation and prognosis.

Mozessohn L, Cheung MC, Crump M, Buckstein R, Berinstein N, Imrie K, Kuruvilla J, Piliotis E, Kukreti V.

Leuk Lymphoma. 2014 Mar 7. [Epub ahead of print]

PMID:
24450580
[PubMed - as supplied by publisher]
13.

Oligoclonal and monoclonal bands after single autologous stem cell transplant in patients with multiple myeloma: impact on overall survival and progression-free survival.

Jimenez-Zepeda VH, Reece DE, Trudel S, Franke N, Winter A, Chen C, Tiedemann R, Kukreti V.

Leuk Lymphoma. 2014 Feb 24. [Epub ahead of print]

PMID:
24354684
[PubMed - as supplied by publisher]
14.

The ASH Choosing Wisely®campaign: five hematologic tests and treatments to question.

Hicks LK, Bering H, Carson KR, Kleinerman J, Kukreti V, Ma A, Mueller BU, O'Brien SH, Pasquini M, Sarode R, Solberg L Jr, Haynes AE, Crowther MA.

Hematology Am Soc Hematol Educ Program. 2013;2013:9-14. doi: 10.1182/asheducation-2013.1.9.

PMID:
24319155
[PubMed - in process]
Free Article
15.

The ASH Choosing Wisely® campaign: five hematologic tests and treatments to question.

Hicks LK, Bering H, Carson KR, Kleinerman J, Kukreti V, Ma A, Mueller BU, O'Brien SH, Pasquini M, Sarode R, Solberg L Jr, Haynes AE, Crowther MA.

Blood. 2013 Dec 5;122(24):3879-83. doi: 10.1182/blood-2013-07-518423. Epub 2013 Dec 4.

PMID:
24307720
[PubMed - indexed for MEDLINE]
16.

Autologous stem cell transplant is an effective therapy for carefully selected patients with AL amyloidosis: experience of a single institution.

Jimenez-Zepeda VH, Franke N, Reece DE, Trudel S, Chen C, Delgado DH, Winter A, Mikhael JR, Tiedemann R, Kukreti V.

Br J Haematol. 2014 Mar;164(5):722-8. doi: 10.1111/bjh.12673. Epub 2013 Nov 25.

PMID:
24266428
[PubMed - indexed for MEDLINE]
17.

Bridging efforts to longitudinally improve and evaluate VEnous thromboembolism prophylaxis uptake in hospitalized cancer patients through Interprofessional Teamwork (BELIEVE IT): a study by Princess Margaret Cancer Centre.

Seki JT, Vather T, Atenafu EG, Kukreti V, Krzyzanowska MK.

Thromb Res. 2014 Jan;133(1):34-41. doi: 10.1016/j.thromres.2013.10.025. Epub 2013 Oct 23.

PMID:
24210735
[PubMed - in process]
18.

Central nervous system involvement with multiple myeloma: long term survival can be achieved with radiation, intrathecal chemotherapy, and immunomodulatory agents.

Chen CI, Masih-Khan E, Jiang H, Rabea A, Cserti-Gazdewich C, Jimenez-Zepeda VH, Chu CM, Kukreti V, Trudel S, Tiedemann R, Tsang R, Reece DE.

Br J Haematol. 2013 Aug;162(4):483-8. doi: 10.1111/bjh.12414. Epub 2013 Jun 15.

PMID:
23772701
[PubMed - indexed for MEDLINE]
19.

Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study.

Jakubowiak AJ, Siegel DS, Martin T, Wang M, Vij R, Lonial S, Trudel S, Kukreti V, Bahlis N, Alsina M, Chanan-Khan A, Buadi F, Reu FJ, Somlo G, Zonder J, Song K, Stewart AK, Stadtmauer E, Harrison BL, Wong AF, Orlowski RZ, Jagannath S.

Leukemia. 2013 Dec;27(12):2351-6. doi: 10.1038/leu.2013.152. Epub 2013 May 14.

PMID:
23670297
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Safety and efficacy of CHOP for treatment of diffuse large B-cell lymphoma with different combination antiretroviral therapy regimens: SCULPT study.

Wong AY, Marcotte S, Laroche M, Sheehan NL, Kukreti V, Routy JP, Lemieux B, Seki JT, Rouleau D, Tseng A.

Antivir Ther. 2013;18(5):699-707. doi: 10.3851/IMP2572. Epub 2013 May 2.

PMID:
23640963
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk